AMPA受体
转移
神经科学
癌症
兴奋性突触后电位
生物
癌细胞
黑色素瘤
谷氨酸受体
脑转移
乳腺癌
癌症研究
医学
抑制性突触后电位
受体
内科学
作者
Varun Venkataramani,Matthia A. Karreman,L. Nguyen,Cedric Tehranian,Nils Hebach,Chanté D. Mayer,L. Meyer,Sadaf S. Mughal,Guido Reifenberger,Jörg Felsberg,Karl Köhrer,Michael C. Schubert,Dana Westphal,Michael O. Breckwoldt,Benedikt Brors,Wolfgang Wick,Thomas Kuner,Frank Winkler
出处
期刊:
[Cold Spring Harbor Laboratory]
日期:2024-01-08
被引量:16
标识
DOI:10.1101/2024.01.08.574608
摘要
Abstract Interactions between neurons and cancer cells are found in many malignancies, but their relevance for metastatic organ colonization remain largely unknown. It is also unclear whether any direct synaptic communication between neurons and cancer cells of non-neural tumor types exists, and if so, whether this can support metastasis and thus cancer progression. Here we show that excitatory synapses are formed between neurons and brain-metastatic melanoma and breast cancer cells. This starts at an early microscopic stage after extravasation into the brain parenchyma, during residence of cancer cells in the perivascular niche, a critical step for their survival. These neuron-cancer synapses showed a bona fide synaptic ultrastructure, and generated excitatory postsynaptic currents mediated by glutamate receptors of the AMPA subtype in cancer cells. In accordance, AMPA receptor signatures were consistently detected in preclinical and patient samples of melanoma and breast cancer brain metastases. Genetic perturbation and pharmacological inhibition of AMPA receptors with the approved antiepileptic drug perampanel in models of breast and melanoma cancer reduced the number of brain metastases and overall brain metastatic burden. These findings demonstrate for the first time that neurons can form biologically relevant direct synapses with non-neural cancer cells. In brain metastasis, a particularly challenging complication of many common malignancies, this non-canonical stimulatory synaptic interaction offers novel therapeutic opportunities.
科研通智能强力驱动
Strongly Powered by AbleSci AI